The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Zacks Investment Research on MSN
J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.
Indivior PLC today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses ...
NanoPass Technologies expands global reach with four new distribution agreements across Singapore, Mexico, Colombia, and Australia, reinforcing its leadership in precision, comfort, and control With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback